GT Biopharma Inc. Common Stock

GT Biopharma announced its third cancer drug, GTB-5550, entered Phase 1 clinical trials on May 14, 2026, marking the company's first expansion into solid tumors. Despite having three drugs in human trials—unusual for a micro-cap—the company trades at a significant valuation discount compared to peers, with only ~$9 million in cash and a runwa...

A new generation of immuno-oncology therapies targeting historically immunotherapy-resistant solid tumors like prostate and pancreatic cancer is advancing rapidly through clinical trials in 2026. Four distinct mechanistic approaches—including NK cell engagers, oncolytic virus immune-primers, and tumor microenvironment-conditional antibodies—a...

The market is shifting focus towards technologies that can detect previously invisible threats across healthcare, resource exploration, and diagnostics, with several companies developing innovative solutions for cardiac care, diabetes treatment, cancer therapy, and mineral exploration.

Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.

GT Biopharma reported progress on its Phase 1 clinical trial for GTB-3650, a TriKE® therapy targeting CD33-expressing hematologic malignancies, with successful advancement to Cohort 4 and no observed safety issues. The company plans to provide a trial update in Q1 2026 and anticipates submitting an IND for GTB-5550 in late December 2025.